In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.

Mult Scler Relat Disord · 2023 · PMC10008178 · PMID 36933299

Europe PMC DOI

hedged sentence

0.2400

closest p · 4.8× alpha

0.2400

boldest claim

The sentences

did not reach statistical significancep = 0.24not close (p > 0.1)

In the untreated MS group 25.8% of subjects had 2 protective immune variables, similarly to alemtuzumab treated patients (25%, p = 0.96), while higher prevalence of 40% was noted in patients treated with teriflunomide, but this difference did not reach statistical significance ( p = 0.24).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.